We conducted a Phase I study evaluating the combination of ficlatuzumab (AV-299), a humanized anti-HGF IgG1 mAb, and cetuximab in patients with recurrent/metastatic HNSCC. Here, HGF is linked to head and neck squamous cell carcinoma.